G 3139: Augmerosen, Bcl-2 antisense oligonucleotide - Genta, GC 3139, Genasense

Drugs in R and D

Volumn 3, Issue 1, 2002, Pages 44-49

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APOPTOSIS INHIBITOR; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IRINOTECAN; MITOXANTRONE; OBLIMERSEN; PACLITAXEL; PROTEIN BCL 2; TAXANE DERIVATIVE; NUCLEOTIDE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER RESEARCH; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INFORMATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; HUMAN; LETHARGY; LEUKOPENIA; MAXIMUM TOLERATED DOSE; MELANOMA; MOUSE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SKIN INFLAMMATION; THROMBOCYTOPENIA; TREATMENT INDICATION; ANIMAL; MALE; NEOPLASM; PROSTATE TUMOR; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MELANOMA; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PROSTATIC NEOPLASMS; THIONUCLEOTIDES;

EID: 0036364987     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200203010-00010     Document Type: Article

References (20)

1. Webb A, Cunningham D, Cotter F, Clarke PA, di Stefano F, et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet. 349: 1137-114, 19 Apr 1997. England. [English]
2. Raynaud F, Foster L, Judson I, et al. Clinical pharmacokinetics of G3139, oligonucleotide antisense to Bcl-2. 89th Annual Meeting of the American Association for Cancer Research. : 521, 28 Mar 1998. England. [English]
3. Genta Incorporated. Investigator reports on results on Genta's antisense product G3139 in malignant melanoma trial presentation at the Cold Spring Harbor Conference on Programmed Cell Death. Media Release. : [3 pages], 1 Oct 1999. Available from: URL: http://www.genta.com. USA. [English]
4. Cunningham D. Webb A, Waters JS, et al. Preliminary results of a phase I trial of antisense to Bcl-2 in non Hodgkin's lymphoma. Eighth International Congress on Anti-Cancer Treatment. : 118, 3 Feb 1998 England. [English]
5. Cotter FE. BCL-2 antisense therapy: in vitro, in vivo and human trial experiences in haematological malignancies. Naunyn-Schmiedeberg's Archives of Pharmacology. 358 (Suppl 1): 205, No. 1, 1998. England. [English]
6. Waters JS, Webb A, Cunningham D, et al. Results of a phase I clinical trial of BCL-2 antisense molecule G3139 (GENTA) in patients with non-Hodgkin's lymphoma. 35th Annual Meeting of the American Society of Clinical Oncology. 18: 4, 15 May 1999. England. [English]
7. Jansen B, Wacheck V, Heere-Ress E, et al. A phase I/II study with dacarbazine and bcl-2 antisense oligonucleotide G3139 (GENTA) as a chemosensitizer in patients with advanced malignant melanoma. 35th Annual Meeting of the American Society of Clinical Oncology. 18: 531, 15 May 1999. Austria. [English]
8. Morris MJ, Tong WP, Cordon-Cordo C, Drobnjak M, Kelly WK, et al. A phase I trial of BCL2 antisense drug G3139 (Genta, Inc.) delivered by continuous intravenous infusion alone and in combination with weekly paclitaxel. Clinical Cancer Research. 5 (Suppl): 3732-3733, Nov 1999. USA. [English]
9. Tolcher AW, Kuhn J, Basler J, Ochoa L, Schwartz G, et al. A phase I, pharmacokinetic and biologic correlative study of G3139 (Bcl-2 antisense oligonucleotide) and docetaxel in patients with hormone-refractory prostate cancer. 11th NCI-EORTC-AACR symposium on new drugs in cancer therapy. : 148 (plus poster), 7 Nov 2000. USA. [English]
10. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, Van Elsas A. et al. bcl-2 Antisense therapy chemosensitizes human melanoma in SCID mice. Nature Medicine. 4: 232-234, Feb 1998. Austria. [English]
11. Genta Incorporated. Investigators report Genta's antisense drug combined with standard chemotherapy cures human lymphomas and breast cancers in mouse models. Media Release. : [3 pages], 19 Apr 1999. Available from: URL: http://www.frbinc.com. USA. [English]
12. Genta Incorporated. Major progress in aggressive cancer type reported for Genta'a lead antisense drug. Media Release. : [1 page], 14 Apr 2000. Available from: URL: http://www.genta.com. USA. [English]
13. Genta Incorporated. Multiple myeloma reported responsive to Bcl-2 antisense treatment. Media Release. : [3 pages], 4 Dec 2000. Available from: URL: http://www.genta.com. USA. [English]
14. Genta Incorporated. New data reaffirm Genta's molecular target as critical factor for enhancing anticancer treatment. Media Release. : [3 pages], 27 Mar 2001. Available from: URL: http://www.genta.com. USA. [English]
15. Genta Incorporated. Genasense (TM) shown to be highly synergistic with additional anticancer drugs at European Hematology Meeting. Media Release. : [2 pages], 25 Jun 2001, Available from: URL: http://www.genta.com. USA. [English]
16. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, et al. Systemic treatment with bcl-2 antisense down-regulates tumor content of bcl-2 protein and induces major antitumor responses in patients with melanoma when combined with dacarbazine. 91st Annual Meeting of the American Association for Cancer Research :late-breaking abstracts. : 7, 1 Apr 2000. Austria: English]
17. Genta Incorporated. Genta's lead antisense drug reported active in malignant melanoma new data on antisense mechanism and clinical response reported in leading journal. Media Release. : [3 pages], 17 Nov 2000. Available from: URL: http://www.genta.com. USA. [English]
18. Jansen B. Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C. et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet. 356: 1728-1733, 18 Nov 2000. Austria. [English]
19. Genta Inc. Genta gets early positive results of Genasense clinical trial, Media Release. : [3 pages], 13 Nov 2000. Available from: URL: http://www.genta.com. USA. [English]
20. Cancer Therapy & Research Center. G3139 (Genasense (TM)) in combination with docetaxel (Taxotere (Rm)) shows promise in advanced prostate cancer. Media Release. : [4 pages], 12 May 2001. USA. [English]